Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1188/08.ONF.171-172 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vaccine Strategies Against RNA Viruses: Current Advances and Future Directions.
Vaccines (Basel)
November 2024
Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan.
The development of vaccines against RNA viruses has undergone a rapid evolution in recent years, particularly driven by the COVID-19 pandemic. This review examines the key roles that RNA viruses, with their high mutation rates and zoonotic potential, play in fostering vaccine innovation. We also discuss both traditional and modern vaccine platforms and the impact of new technologies, such as artificial intelligence, on optimizing immunization strategies.
View Article and Find Full Text PDFAntibacterial and Anti-Influenza Activities of -Heterocyclic Carbene-Gold Complexes.
Pharmaceuticals (Basel)
December 2024
Department of Life, Health and Environmental Sciences, University of L'Aquila, Piazzale Salvatore Tommasi 1, Blocco 11, Coppito, 67010 L'Aquila, Italy.
Background/objectives: Infectious diseases represent a serious threat due to rising antimicrobial resistance, particularly among multidrug-resistant bacteria and influenza viruses. Metal-based complexes, such as -heterocyclic carbene-gold (NHC-gold) complexes, show promising therapeutic potential due to their ability to inhibit various pathogens.
Methods: Eight NHC-gold complexes were synthesized and tested for antibacterial activity against , , and for anti-influenza activity in lung and bronchial epithelial cells infected with influenza virus A/H1N1.
Emerging Therapeutics in the Fight Against EV-D68: A Review of Current Strategies.
Influenza Other Respir Viruses
December 2024
Infection and Immunity Research Strength, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway, Malaysia.
Enterovirus-D68 (EV-D68) was first identified in 1962 in pediatric patients with acute respiratory conditions in California, USA (US). From the 1970s to 2005, EV-D68 was underestimated due to limited data and serotyping methods. In 2014, the United States experienced outbreaks of acute flaccid myelitis (AFM) in children EV-D68 positive.
View Article and Find Full Text PDFSafety, tolerability, and efficacy of intranasally-administered detoxified LTh(αK) in mild-to-moderate COVID-19 patients: A randomized, double-blinded, placebo-controlled phase 2 study.
Hum Vaccin Immunother
December 2024
Molecular Infectious Disease Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
The objective of the study was to assess the safety, tolerability, and potential efficacy of intranasally administered AD17002, a detoxified form of heat-labile enterotoxin, in treating individuals with mild-to-moderate coronavirus disease of 2019 (COVID-19). In this randomized, double-blinded, and placebo-controlled phase 2a study, a total of 30 adults aged 20-70 years with mild-to-moderate COVID-19 were recruited from three medical centers in Taiwan in 2022-2023. The trial comprised two cohorts, and participants were randomly assigned to receive intranasal administrations of either three doses of AD17002 immunomodulator or a placebo formulation buffer.
View Article and Find Full Text PDFOceanic Breakthroughs: Marine-Derived Innovations in Vaccination, Therapy, and Immune Health.
Vaccines (Basel)
November 2024
Institute of Biostructures and Bioimaging, Italian National Research Council (IBB-CNR), Via P. Castellino 111, 80131 Naples, Italy.
The vast, untapped potential of the world's oceans is revealing groundbreaking advancements in human health and vaccination. Microalgae such as spp. and are emerging as resources for recombinant vaccine development with specific and heterologous genetic tools used to boost production of functional recombinant antigens in and spp.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!